) Description For the year ending 31 December Year Increased (decreased) 2017 2016 Amount % Total revenues 815.31 791.94 23.37 2.95 Total expenses and finance cost 782.71 762.13 20.58 2.70 Share of profit from
Summary Financial Ratio 2016 2015 2014 LIQUIDITY RATIO Liquidity Ratio Times 3.90 3.46 3.24 Quick Ratio Times 3.50 3.09 2.73 Current Ratio Times 1.33 1 1.02 Account Receivable Turnover Times 7.48 7.52 6.52
) % December , December , Assets . . . . % Liabilities . . . . % Shareholders' equity . . . . % Issued and fully paid-up common share (Million Share) . . . . % Par (Baht) . . . . % 4.1 Assets Overall asset as at
be a potential market in the future. For Medical Devices; There is still intense competition in both domestic and foreign markets. Market leaders use price strategies to gain market share. But the
Company has been awarded ISO 13485, the Quality Management System for Medical Device Industry which is an important tool for competition and maintaining the product’s market share), the Company can maintain
49.34 17.69% Finance cost 49.11 68.10 18.99 38.67% Income tax expenses 48.04 57.52 9.48 19.73% Net profit 181.71 202.58 20.87 11.49% Net profit ratio (ROS) 17.16% 15.74% Earnings per share (Baht) 0.34
67.37 94.72 27.35 40.60% Income tax expenses 59.19 65.40 6.21 10.49% Net profit 227.68 252.81 25.13 11.04% Net profit ratio (ROS) 16.00% 14.78% Earnings per share (Baht) 0.37 0.42 0.05 13.51% Total
, claiming returns from cryptocurrencies, digital tokens or package investment plans in the form of Ponzi scheme. Solicitors may also promise or guarantee attractive returns, luring investors into quick
expenses 192.25 167.67 (24.59) (12.79%) Net profit 744.83 716.45 (28.38) (3.81%) Net profit attributable to owner of the parent 735.44 706.19 (29.25) (3.98%) Earnings per share (EPS) 0.44 0.42 (0.02) (3.98
) EBIT 145.81 12.74 149.40 13.67 (3.59) (2.40) NP 115.58 10.09 116.50 10.66 (0.92) (0.79) EPS (Baht per Share) * 0.12 - 0.12 - - - Weighted Average Number of Ordinary Shares (Million Shares) * 947.96